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Table 1. Clinical Patient Data in 31 Cases septum. one for the determination of catecholamine content ___I~ 
Age lyr) Duration of nnd the remainder for histologic examination. in eight pa- 
&e EF PC NYHA Srmelcm~. Cents an additional endomyocardial biopsy was performed 
No. m Gender Cl%% ’ Ifi”) 
I 15 4OM 
2 a0 EM 
3 20 SOF 
4 !I 62F 
s 21 62M 
6 23 SOF 
1 27 SOM 
8 2X 40F 
9 2R 29M 
IO 30 47M 
II 31 55M 
I2 33 43F 
13 34 49M 
14 34 49M 
IS 34 6OF 
I6 36 33M 
17 37 36M 
I8 38 65M 
I9 39 . 56M 
20 41 31M 
21 44 43M 
22 45 57M 
23 47 5fiM 
24 47 45M 
25 49 36M 
26 50 59M 
27 53 6llM 
2R 54 49111 
29 63 5lM 
30 79 49M 
31 79 45M 
4 
4 
4 
3 
4 
3 
3 
4 
2 
3 
3 
3 
3 
3 
3 
2 
3 
3 
3 
2 
2 
2 
I 
2 
2 
I 
2 
! 
I 
I 
I 
x4 
I44 
24 
60 
24 
14 
I5 
MI 
34 
e 
I? 
0 
I? 
C.lpiMg1IFur 
C.~plDipiFur 
C;lplDlgolFur 
C;~p/ll~gllFUr 
Cap. ISDN/Fur 
CilplDigoiHydro. TKL 
C,lplDigilHydro. T~I;I 
C;~plDspolFur 
ISDNiDigoiHydro. 
Tria 
CapiDigolHydro. Trru 
CaplD~go 
CaplD~go 
C;tp/Digo 
Capliligo 
DigilHydro. Tna 
Cap 
CaplDignlHydro. Tria 
CdplHydro 
Cap.MoUDignlHydro 
Cap/Hydra. Triu 
CaplDigonlHydro, i’rw 
ISDNlDigolHydro. 
Triil 
CaplDigolHydro. Tria 
CaplDigolHydro. Tria 
Cap/Fur0 
DlgilHydro. Tna 
Nif 
- 
Caw 29 lo 31 are patient5 without evidence of cardiac diwase. Cap = 
eaptopril; Digi = digitoxin: Digo = digoxin: EF = ejection fmction: F = 
female; Fur = furosemidc: Hydro = hydroehlorothiazide: ISDN = iworbide 
dinitrate; M = male; Mol = molsidomine; Nif = mfedipme. NYHA = New 
York Heart Awociation: Tria = triamterene. 
logic findings. These three patients were considered to have 
no organic heart disease. The indication for biopsy in the 
remaining 28 patients was unexplained left ventricular dys- 
function that bad lasted for an average of 24 months (range 3 
to 144). At the time of study, IS patients were receiving a 
combination of digitalis, a diuretic and a vasodilator; 4 were 
receiving digitnliq and a vasodilator; 2 were receiving digi- 
talis and a diuretic; 4 were receiving a vasodiiator and a 
diuretic; 2 were receiving a vasodilator; and the remaining 4 
were without medication. 
Endomyucardial biopsy. Endomyocardial biopsy was 
performed with a Yacoub bioptome after insertion of a 
sheath into the internal jugular vein. Four to six biopsy 
samples were taken from the right side of the interventricular 
2. to 6 h after l-123 me&-iodobenzy&midine (MIBG) 
injection. The activity of the samples was measured directly 
in the scmtillation counter and then corrected by the con- 
stanl cf decay and normalized to a fixed injected dose. I- I23 
MIBG activity from biopsy samples was thencompared with 
l-123 MIBG activity from the myocardial septum. 
After 20 min of supine rest, 5 ml of venous blood was 
taken for measurement of plasma catecholamines. Coronary 
itnd left ventricular cineangiography were then performed. 
Myocardial and plasma catecholamine c~lccentratians. 
For the determination of myocardial catecholamine concen- 
trations, biopsy samp!es were frozen in liquid nitrogen 
immediately after retrieval. After measurement of the wet 
weight the tissue was homogenized in perchloride acid with 
the addition of ethylene glycol tetraacetic acid and glutathi- 
one. After centrifugation, catecholamines were determined 
from the supernatant by a radioenzymatic method (3). The 
lowest detection limits were 3 pg of norepinephrine and 
epinephrine and 4 pg of dopamine. The same radioenzymatic 
method was used to measure plasma catecholamines. 
Left ventricular ejection fraction. This variable was de- 
termined from right anterior oblique 30” left ventricular 
angiogram5. and Simpson’s rule was used for left ventricular 
volume measurements (4). 
l-123 metakdobenzylguanidine (MIBG) scintigraphy. 
The time interval between endomyocardial biopsy and 1-123 
MtBG scintigraphy was ~2 months in 21 patients, <6 
months in 4 patients and ~12 months in the remaining 3 of 
the 28 patients in whom myocardial catecholamines could be 
determined. Informed consent for endomyocardial biopsy 
and scinligraphy was obtained from each patient. 
l-123 r~etrr-iodohenzyl~lprrarlidine (MIBG) scinrigraphy 
was performed after blockade of thyroid uptake of free I-123 
by sodium perchlorate. P&ients were at rest in the supine 
position for I h before l-123 MIBG injection and during the 
whole study period. Five milticuries of I-123 MIBG was 
injected intravenously and scintigrams were obtained in the 
anterior and left anterior oblique 30” and 60’ views at I, 2,6 
and 24 h after injection. A standard field of view camera 
(LEM. Searle) connected to a mobile data acquisition sys- 
tem (PDP 11134. gamma II) was used. The camera was 
equipped with a low energy, high resolution collimator. A 
25% window was used and was centered at 159 keV. One 
million counts per view were collected. 
Qualitative scintigrophic analysis. The scintigrams were 
judged by three independent observers using the fotlowing 
score system: score I = distinct myocardial J-123 meta- 
iodobenrylguanidine (MIBG) uptake without defects; score 
2 = myocardium clearly visible but diffusely reduced uptake 
or circumscribed defects: and score 3 = myocardium shad- 
owy or not visible. 
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Quantitative scintigrapltic analysis, Data were recorded 
in a 128 x 128 matrix and stored on a disc. Regional I-123 
meta-iodobenzylguanidine (MIBG) uptake in the myocar- 
dium, lungs, liver and mediastinum was measured in small 
regions of interest and expressed as average counts/pixel. 
For determination of the heart to mediastinum ratio the 
activity in the myocardium was measured in a hand-drawn, 
sickle-shaped region free of background activity from liver 
and lungs. For a comparison of data the measured count 
rates were corrected by the following factor: 
(!y exp 
where h = 13.3 h (half-time of iodine-123); d = duration of 
measurement (in seconds): a, = baseline activity of I-123 
befool, injection; At, = time interval from I-123 MIBG 
injection to start of scintigraphic measurements (in hours); 
and At, = time interval from measurement of baseline 
activity to l-123 MlBG injection. Calculations were repeated 
after background correction with use of the interpdation 
technique described by Goris et al. (S), 
Determination of I-123 meta-i&benzylgmnMine (MPG) 
blood activity. Blood was sampled for determination oil-123 
MIBG activity 2 and 6 h after injection of the radiotracer and 
measured in the scintillation counter. 
Statistics. For evaluation of differences between groups 
of patients, the Mann-Whitney U test was used, and for 
evaluation of the relation between different variables a linear 
regression analysis was peifonned. 
Results 
Qualitative scintigral+ic data (Fig. 1). Distinct myocar- 
dial Ifdine-123 (I-123) meta-iodobenzylguanidine (MIBG) 
uptake with no defect (score i) was found in 7 patients; 17 
patients had a scintigraphic score of 2, and the remaining 7 
patients had a score of 3. Mean left ventricuIar ejection 
fraction of patients with score 1 was 58 + 16% (mean + 1 
SD), which was significatly higher than that of patients with 
score 2 (38 2 9%; p < 0.05). Patients with score 2 had a 
significantly higher ejection fraction than did patients with 
score 3 (23 f 6%, p < 0.002). No such relation was found 
between the scintigraphic scores and the duration of symp 
tams or the New York Heart Association functional class. 
Qaantitative scintigqhii data (Table 2). I-123 meta- 
iodobenzylguanidine (MIBG) activity in the myocardial re- 
gions of interest 2 h after I-123 MIBG injection did not differ 
from the activity determined 6 h after injection (8.9 t I.5 
versus 8.5 2 1.5 X 10e4 counts per injected activity per pixel 
per s)+ 
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Trhle 2. Scintigraphic Patient Data in 31 Cases 
CLse No. 
I 
2 
3 
4 
5 
6 
7 
8 
9 
IO 
II 
12 
I3 
I4 
I5 
16 
I7 
I8 
I9 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
Myocardial Aclwity’ Medm~linal Activiry’ 
?h bh Zh 6h 
6.1 4.6 6.0 4.4 
8.1 56 7.0 5.0 
7.‘) 6.5 7.8 6.4 
8,9 7.h 1.9 7.3 
6.3 4.9 5.1 4.0 
9.4 7.2 7.5 6.6 
8.1 6.2 7.2 6. I 
9.8 9.3 8.0 7.7 
10.9 9.4 8.0 64 
8.8 6.9 7.4 5.9 
7.4 6.1 6.3 5.3 
II.9 9.0 8.3 6.3 
8.1 7.0 6.0 5.8 
8.7 5.5 7.0 4.7 
8.2 6.3 7.0 4.7 
6.7 5.2 5.2 4.1 
10.2 8.7 7.2 6.0 
8.5 5.9 6.4 5.0 
9.1 7.6 5.8 5.0 
7.8 5.3 5.7 3.6 
8.6 6.8 j.i 4.0 
6.4 4.9 4.8 3.7 
IO.0 8.4 6.8 6.0 
8.fJ 6.3 5.s 4.3 
10.0 8.0 7.6 5.8 
7.3 5.3 5.4 4.5 
8.1 6.3 5.4 4.1 
7.0 5.8 5.5 4.2 
9.9 7.1 7.3 5.2 
9.6 8.4 6.3 5.5 
8.7 6*7 5.8 4.1 
MyocardidllMediaslinal 
Aclwity hatio 
2h 
IO2 
I Ih 
102 
113 
I23 
126 
II3 
123 
137 
I20 
II7 
143 
I34 
126 
II8 
129 
I41 
I34 
I58 
137 
I52 
I33 
146 
:49 
132 
136 
I50 
127 
I58 
I51 
ISI 
Lung Aclivily* 
.- 
Zh 6h 
7.6 5.9 
9.8 5.9 
14.3 12.5 
11.4 9.0 
5.7 4.8 
11.0 8.8 
7.6 6. I 
13.0 8.4 
8.0 5.9 
8.6 7.0 
10.5 8.3 
9.0 8.2 
8.4 6.2 
8.6 5.6 
12.3 8.9 
5.2 4.1 
8.2 7.2 
9.4 7.3 
12.1 7.8 
7.8 5.2 
7.1 4.9 
5.6 4.1 
7.8 6.2 
3.2 6.8 
10.0 7.7 
6.1 4.6 
1.4 6.7 
8.3 6.0 
8.5 5.9 
9.3 7.4 
9.5 5.8 
Liver Activily’ 
2h 6h 
il.4 7.6 
23.9 8.5 
29.4 20.0 
18.3 II.1 
12.6 8.4 
23.6 12.3 
16.5 16.1 
23.6 12.6 
z4.2 19.9 
13.3 15.7 
14.5 11.3 
17.2 19.2 
19.5 16.5 
16.2 10.2 
21.5 19.7 
15.1 9.6 
29.8 22.3 
20.1 15.5 
14.7 14.2 
20.5 II.6 
18.0 14.5 
12.5 8.0 
f7.8 13.8 
2l-l I 20.0 
15.2 II.3 
II.6 9.8 
18.7 If.8 
15.7 13.5 
16.6 19.5 
17.8 15.6 
21.4 13. I 
*In IO-” counts per injected activity per pixel per s. 
tigraphy. was found between the myocardial versus me- 
diastinal I-123 MIBG activity ratio and myocardial norepi- 
nephrine content (r = 0.63) (Fig. 2). No such correlation was 
found between myocardial I-123 MIBG uptake and the 
epinephrine and dopamine concentrations in the myocar- 
dium. The scintigraphic myocardial versus mediastinal I-123 
MIBG activity ratio was also not correlated with the plasma 
catecholamine concentrations. A positive correlation (r = 
0.74) (Fig. 3) was found between left ventricular ejection 
fraction and the myocardial versus mediastinal I-123 MIBG 
uptake ratio. There was no correlation between the scinti- 
graphic data and the duration of symptoms or New York 
Heart Association functional class. 
After background correction, correlations between I) the 
scintigraphic data and 2) the myocardial norepinephrine 
content and left ventricu!x ejection fraction were not dif- 
ferent from those obtained with the uncorrected data. 
Discllssion 
Myocardial imaging wilh iodine-123 (I-123) m&i-W* 
zyylguanidine. The sympathetic nervous system may play a 
role in the development and progression of idiopathic dilated 
cardiomyopathy. In a recent endomyocardial biopsy study 
(6) we found a close relation between myocardial norepi- 
nephrine content determined from transvenous endomyocar- 
dial biopsy and left ventricular function. This relation was 
apparently independent d the degree of muscle fiber hyper- 
trophy, volume fractior of intetstitium and plasma catechol- 
amine concentration, sqgesting that myocardial norepi- 
nephrine depletion is a better indicator of the status of the 
disease than are these variables. We used I-123 MIBG 
scintigraphy to study cardiac adrenergic nerve activity in 
dilated cardiomyopathy noninvasively. Other investigators 
(2) previously showed that myocardial imaging with I-123 
MiBG is possible in humans. The present report is the lhst 
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Table 3. Plasma and Myocardial Catcchotaminr Values in ZY Cases 
Plasma Pla\mn Myucnrdial 
Case Narepincphrine Epinephrine Nurrpinephrine 
No. (pe/mll Ip~ml) (pglmgl 
MyOCilrdial Myocardial 
Epinephrinr Dupamine 
(pg/ml) (pg/mf3) 
327 28 149 40 91 
2 - - 380 I5 I:. 
3 469 87 21 3 58 
4 248 299 - - 
5 172 136 I158 I6 106 
6 564 IX III02 23 62 
7 - - - - 
8 
9 
ICI 
II 
I2 
I3 
14 
I5 
16 
17 
435 
109 
794 
542 
loo 
362 
201 
SO5 
115 
349 
560 642 
79 I9X6 
88 378 
94 263 
33 I949 
38 I’)0 
80 2n2 
79 2% 
222 242 
73 660 
44 
nm 
II 
4 
3 
42 
4 
22 
42 
77 
26 
I5 
166 
nm 
4 
IO 
nm 
137 
I8 - - - - - 
IY 186 I2 14411 60 173 
20 - - 423 II9 174 
21 282 73 I.567 88 YI 
22 614 nm 495 204 I95 
23 23.5 I22 1111 21 23 
24 - - l7W I I5 I70 
25 776 I58 906 225 3M 
26 44 I7 432 2tl 60 
27 iU7 203 523 2% W 
28 - - 242 30 55 
29 215 IW 1413 21 84 
30 341 48 1566 24 15 
31 XI4 65 381 nm 40 
nm = not measurable. 
description of a larger number of patients with a specific 
cardiac disease in whom I-123 MIBG scintigraphic data were 
examined in relation to clinical and hemodynamic variables 
as well as to plasma and myocardial catechokimine concen- 
tra!ions. To assess potentia! differences in !he scintigraphic 
findings, patients with different degrees of left ventricular 
dysfunction and three patients without cardiac disease were 
included in the study. As a consequence, patients received 
various medications or had no therapy at the time of study. 
However, no drug with a direct action on the sympathetic 
nervous system was given to any patient. 
Qualitative scintigraphic analysis. By judging the scinti- 
grams qualitatively, patients could be classified into three 
groups: one group with a distinct myocardial i-123 mela- 
iodobenzylguanidine {MLBG) uptake, one group with re- 
duced uptake or defects but clear visualization of the heart 
and a third group with barely visible or no visible myocardial 
uptake. The degree of left ventricular dysfunction in the 
three groups differed in parallel with the scintigraphic find- 
ings. 
Quantitative scinligraphii analysis. I-123 meta-iodoben- 
zylguanidine (MIBGf scintigraphic data were also analyzed 
quantitatively. Background correction (5) did not appear to 
be useful, as was evident from a crmparison of the data with 
those obtained without background subtraction. The best 
quality scintigrams were obtained 2 h after I-123 MIBG 
injection, which was reflected by a slightly higher myocar- 
dial versus mediastinal I-123 MlBG activity ratio than that 
obtained 6 h after injection. Nakajo et al. (7) found the 
highest intravesicular percent of total cardiac tissue I-123 
MlBG concentration 4 h after intravenous injection of I-123 
MIBG. Extravesicular l-123 MIBG accumulation in their 
study was highest immediately after I-123 MIBG application 
and decreased rapidly over the next 6 h. 
When I-123 MIBG activity in the interventricularseptum was 
compared with the activity in biopsy samples taken from the 
same region, a positive correlation was found. This indicates 
that the scintigraphically measured I-123 MIBG activity corre- 
sponds to I-123 MIBG activity in the myocardium. 
JACC Vol. 12. No. 5 SCHOFER ET AL. 
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Figure 2. Relation between myocardial norepinephrine content and 
the myocardial versus mediastinal iodine- 123 meta-iodobenzylgua- 
nidine (MIBG) activity ratio in 28 patients with dilated cardiomyop- 
athy. 
Figure 3. Relation between left ventricular ejection fraction and the 
myocardial versus mediastinal iodine-123 meta-iodobenzy;guanidine 
(MIBG) activity ratio in 31 ptients. 
imental study. They demonstrated that injury to adrenergic 
scintigraphy versus myocardial and plasma catechol- nerves has a less pronounced effect on I-123 MIBG uptake 
amines. A positive correlation was also found between than on the uptake of H3 norepinephhe. 
myocardial norepinephrine content and the myocardial ver- Scintigraphy and kft ventric&r finxtioo. Myocardial 
sus mediastinal I-123 MIBG meta-iodobenzytguanidine ac- norepinephrine content decreases with progession of heart 
tivity ratio. This has not been demonstrated before. The failure, as has been shown experimentally (11.12) and in 
rather large variation found between the two variables may patients in whom myocardial biopsy was performed (6). If 
have several causes. First, myocardial norepinephrine dis- myocardial l-123 meta-iodobenzylguanidine (MIBG) uptake 
tribution may not exactly reflect the density of adrenergic reflects the integrity of cardiac adrenergic nerves, a similar 
vesicies thought to be indicated by I- 12: %IBG sciiitigraphp. relation to the degree of ventricular dysfunction as to myo- 
Second, there are pronounced regional differences within the cardial norepinephrine content could be expected. That this 
left and the right ventricle in myocardiaf norepinephrine is indeed the case is demonstrated in this study by the 
content (8). Even in the three patients without cardiac significant positive correlation between myocardiat I-123 
disease we found a smaller apical than basal I-123 MlBG MIBG activity and left ventricular ejection fraction. Wheth- 
uptake. An averaged scintigraphic value from a larger region er our findings are specific for heart failure due to idiopathic 
of the myocardium may better reflect the true status of the cardiomyopathy or are also applicable to patients with heart 
adrenergic nervous system than wouId a small piece of failure of other causes cannot be answered with certainty. 
endomyocardial tissue. A third cause may be the large However, from the results of biopsy studies in which myo- 
variation of the time interval between endomyocardial bi- cardial norepinephrine depletion was demonstrated in pa- 
opsy and l-123 MIBG scintigraphy. However, the relation tients with heart failure due to valvular and coronary artery 
between myocardiai norepinephrine content and myocardial disease (13,14) one might also expect a correlation between 
l-i23 MIBG uptake did not seem to be systematically myocardial l-123 MIBG activity and left ventricular ejection 
influenced by this time interval (Fig. 2). possibly because the fraction in these patients. 
majority of patients (21 of 28) underwent scintigraphy within Conclusions. Our data suggest that myocardial l-123 
2 months of endomyocardial biopsy. meta-iodobenzylguanidine (MIBG) scintigraphy is a useful 
I-123 MIBG uptake in the myocardium may also be noninvasive method to assess myocardial adrenergic ner- 
influenced by the concentration of circulating catechol- vous system disintegrity in patients with idiopathic dilated 
amines (9). Because I-123 MlBG uptake is competitively cardiomyopathy. Further studies are needed to show 
inhibited by circulating catecholamines, an inverse relation whether myocardial I-123 WIBG scintigraphy can clarify the 
between plasma catecholamine concentration and myocar- pathogenetic significance of the sympathetic nervous system 
dial I-123 MIBG activity may exist, as has been demon- in dilated cardiomyopathy and possibly heart failure of 
strated by Nakajo et al. (9) in patients with pheochromocy- another cause, and whether the scintigraphic data can serve 
toma. In our study no such correlation was found, indicating as a prognostic indicator in these patients. 
that even the eIevated plasma catecholamine coccentrations 
present in heart failure do not significantly influence myo- 
cardial I-123 MIBG uptake. References 
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